Page last updated: 2024-11-05

mirex

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mirex: An organochlorine insecticide that is carcinogenic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16945
CHEMBL ID442231
CHEBI ID34852
SCHEMBL ID118586
MeSH IDM0013920

Synonyms (103)

Synonym
BIDD:ER0425
dodecachloropentacyclo[3,2,0(sup2,6),o(sup3,9),0(sup7,10)]decane
2385-85-5
cyclopentadiene, dimer
pentacyclodecane, dodecachloro-
dodecachlorooctahydro-1,4-metheno-2h-cyclobuta[cd]pentalene
perchloropentacyclodecane
bichlorendo
decane,perchloropentacyclo-
paramex
gc 1283
perchloropentacyclo[5.2.1.02,9.05,8]decane
dodecachlorooctahydro-1,4-metheno-1h-cyclobuta[cd]pentalene
perchloropentacyclo[5.2.1.0(sup2,9).0(sup5,8)]decane
hrs l276
dechlorane 515
hexachlorocyclopentadiene dimer
cg-1283
wln: l545 b4 c5 d 4abce jtj-/g 1 2
dechlorane
perchlorodihomocubane
1,4-metheno-1h-cyclobuta[cd]pentalene, 1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-
dodecachloropentacyclodecane
nsc-124102
dodecachlorooctahydro-1,4-metheno-2h-cyclobuta[c,d]pentalene
dechloran plus
nsc124102
mirex
dechlorane 4070
1, 1,2,3,4,5,5-hexachloro-, dimer
nci-c06428
ent 25,719
1,4-metheno-1h-cyclobuta[cd]pentalene, dodecachlorooctahydro-
dodecachlorooctahydro-1,3,4-metheno-2h-cyclobuta[cd]pentalene
1,3,4-metheno-1h-cyclobuta[cd]pentalene, 1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-
nsc-37656
nsc37656
nsc-26107
nsc26107
ccris 413
nsc 124102
1,3-cyclopentadiene, 1,2,3,4,5,5-hexachloro-, dimer
perchloropentacyclo(5.3.0.0(2,6).0(3,9).0(4,8))decane
nsc 26107
fire ant bait
1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-1,3,4-metheno-1h-cyclobuta(cd)pentalene
dodecachlorooctahydro-1,3,4-metheno-1h-cyclobuta(cd)pentalene
ferriamicide
epa pesticide chemical code 039201
ai3-25719
dodecachloropentacyclo(5.2.1.0(2,6).0(3,9).0(5,8))decane
1,3,4-metheno-1h-cyclobuta(cd)pentalene, 1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-
nsc 37656
1,3-cyclopentadiene, 1,2,3,4,5,5-hexachloro-, dimer (van)
perchloropentacyclo(5.2.1.0(2,6).0(3,9).0(5,8))decane
einecs 219-196-6
dodecachloropentacyclo(5.2.1.02,6.03,9.05,8)decane
perchloropentacyclo(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 5,8))decane
dodecaclor
hsdb 1659
caswell no. 411
hrs 1276
1,3,4-metheno-1h-cyclobuta(cd)pentalene, dodecachlorooctahydro-
dodecachloropentacyclo(3.2.2.0(sup 2,6),0(sup 3,9),0(sup 5,10))decane
1,2,3,4,5,5-hexachloro-1,3-cyclopentadiene dimer
perchlordecone
cyclopentadiene, hexachloro-, dimer
CHEBI:34852 ,
1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-1h-1,3,4-(methanetriyl)cyclobuta[cd]pentalene
1,2,3,4,5,5,6,7,8,9,10,10-dodecachloropentacyclo[5.3.0.0(2,6).0(3,9).0(4,8)]decane
perchloropentacyclo[5.2.1.0(2,6).0(3,9).0(5,8)]decane
CHEMBL442231
NCGC00248098-01
unii-z917an264p
z917an264p ,
tox21_300592
NCGC00254525-01
cas-2385-85-5
dtxsid7020895 ,
dtxcid10895
AKOS024319122
mirex (dechlorane 4070)
FT-0603604
mirex [mi]
mirex [hsdb]
mirex [iarc]
dodecachloropentacyclo(5.3.0.0(sup 2,6).0(sup 3,9).0(sup 4,8))decane
SCHEMBL118586
perchlorodecone
dodecachloropentacyclo(3,3,2,0(2,6),0(3,9),0(7,10))decane
1,3,4-metheno-2h-cyclobuta[cd]pentalene, dodecachlorooctahydro-
perchloropentacyclo(5.2.1.0(2,6),0(3,9),0(5,8)decane
GVYLCNUFSHDAAW-UHFFFAOYSA-N
mirex, certified reference material, 1000 mug/ml in acetone
mirex, pestanal(r), analytical standard
mirex 10 microg/ml in isooctane
mirex 100 microg/ml in isooctane
J-015240
Q419578
1,3,4-metheno-1h-cyclobuta[cd]pentalene,1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-
1,2,3,4,5,5,6,7,8,9,10,10-dodecachloropentacyclo[5.3.0.02,6.03,9.04,8]decane
perchlorooctahydro-1h-1,3,4-(epimethanetriyl)cyclobuta[cd]pentalene
mirex 1000 microg/ml in acetone

Research Excerpts

Overview

Mirex is a toxic, hydrophobic pollutant in Lake Ontario that undergoes an indirect photoreaction mediated by natural dissolved organic matter. It is a potent tumor promoter in 7,1 2-dimethylbenz[a]anthracene (DMBA)-initiated female CD-1 mouse skin.

ExcerptReferenceRelevance
"Mirex is a pesticide that is environmentally stable, accumulates in body tissues, and is embryo- and feto-toxic at high concentrations in vivo. "( Embryotoxicity of the pesticide mirex in vitro.
Branch, S; El-Bayomy, AA; Smoak, IW, 2002
)
2.04
"Mirex is a toxic, hydrophobic pollutant in Lake Ontario that undergoes an indirect photoreaction mediated by natural dissolved organic matter. "( Wavelength dependent photoreactivity of mirex in Lake Ontario.
Hassett, JP; Lambrych, KL, 2006
)
2.04
"Mirex is a potent tumor promoter in 7,1 2-dimethylbenz[a]anthracene (DMBA)-initiated female CD-1 mouse skin. "( Evidence that mirex promotes a unique population of epidermal cells that cannot be distinguished by their mutant Ha-ras genotype.
Foley, JF; Kim, TW; Maronpot, RR; Porter, KL; Smart, RC, 1997
)
2.1
"Mirex is an unusually potent and long-lasting inducer of rat hepatic ornithine decarboxylase activity."( Mirex induces ornithine decarboxylase in female rat liver.
Conolly, R; Kitchin, K; Kulkarni, AP; Mitra, A; Richards, I, 1990
)
2.44
"Mirex is an organochlorine chemical with pesticidal and other industrial usages. "( The human body burden of mirex in the southeastern United States.
Carra, JS; Kutz, FW; Leininger, CC; Sparacino, CM; Strassman, SC; Stroup, CR; Watts, DL, 1985
)
2.02

Effects

MiREx has been evaluated on four cancer primary sites from the genomics data commons (GDC) database: lung, kidney, breast, and corpus uteri. Mirex has never been registered for use as an insecticide in Canada.

ExcerptReferenceRelevance
"MiREx has been evaluated on four cancer primary sites from the genomics data commons (GDC) database: lung, kidney, breast, and corpus uteri."( MiREx: mRNA levels prediction from gene sequence and miRNA target knowledge.
Ficarra, E; Lovino, M; Martignetti, L; Pianfetti, E, 2023
)
3.07
"Mirex has never been registered for use as an insecticide in Canada, nor does it appear to be in use in any area of the United States discharging water into Lake Ontario or its tributaries."( Mirex: an unrecognized contaminant of fishes from Lake Ontario.
Kaiser, KL, 1974
)
2.42

Actions

ExcerptReferenceRelevance
"Mirex failed to inhibit steroidogenesis which was supported by exogenous pregnenolone."( Inhibitory effect of chlordecone and mirex on steroid synthesis in Y-1 cells.
Warner, W,
)
1.13

Treatment

Mirex was treated with excess amine in sealed glass tube reactors under nitrogen. Mirex-pretreated rats incorporated [14C]amino acids into liver protein at the same rate as controls, but retained more of the radiolabeled amino acids in liver protein for a longer time. Mice treated with mirex developed a maximum of 6.4 papillomas/mouse.

ExcerptReferenceRelevance
"Mirex was treated with excess amine in sealed glass tube reactors under nitrogen."( Amine promoted, metal enhanced degradation of Mirex under high temperature conditions.
Alley, EG; Jallad, KN; Lynn, BC, 2006
)
1.31
"Mirex-pretreated rats incorporated [14C]amino acids into liver protein at the same rate as controls, but retained more of the radiolabeled amino acids in liver protein for a longer time."( Liver protein synthesis and catabolism in mirex-pretreated rats with enlarging livers.
Robinson, KM; Yarbrough, JD, 1980
)
1.25
"Mirex treatment had no effect on hepatic plasma membrane Na+,K(+)- or Mg2(+)-ATPase activity."( Mirex exposure inhibits the uptake of estradiol-17 beta(beta-D-glucuronide), taurocholate, and L-alanine into isolated rat hepatocytes.
Teo, S; Vore, M, 1990
)
2.44
"Mirex treatment significantly decreased the TC extraction ratio by 40-89% and the hepatic intrinsic clearance by 85-95%."( Mirex inhibits bile acid secretory function in vivo and in the isolated perfused rat liver.
Teo, S; Vore, M, 1991
)
2.45
"Mice treated with mirex developed a maximum of 6.4 papillomas/mouse."( Evidence that mirex promotes a unique population of epidermal cells that cannot be distinguished by their mutant Ha-ras genotype.
Foley, JF; Kim, TW; Maronpot, RR; Porter, KL; Smart, RC, 1997
)
0.98
"Pretreatment with mirex (100 mg/kg, intragastrically) increased liver/body weight ratios and DNA synthesis in livers of fed rats, effects that were markedly diminished in livers of fasted rats."( Carbohydrate and oxygen metabolism during hepatocellular proliferation: a study in perfused livers from mirex-treated rats.
Badr, M; Cunningham, M; Thurman, R; Yamanaka, H; Yarbrough, J, 1991
)
0.82
"Treatment with mirex caused a two-fold induction of cytochrome P-450, and BP-hydroxylase activity expressed per mg microsomal protein was increased 1.3-fold."( Influence of chlordecone and mirex exposure on benzo[a]pyrene metabolism of rat-liver microsomes.
Crouch, LS; Ebel, RE, 1987
)
0.9

Toxicity

The cumulative LD50 for photomirex was estimated as 225-250 mg/kg. These results indicate that photomiresx was approximately five times more toxic than mirex in terms of liver histology.

ExcerptReferenceRelevance
" Oligomycin-sensitive Mg2(+)-ATPase was decreased significantly only starting at 6 hr (21%) after CCl4 administration, indicating that depletion of ATP at early time points was most likely due to rapid utilization consequent to toxic events."( Altered hepatic energy status in chlordecone (Kepone)-potentiated CCl4 hepatotoxicity.
Kodavanti, PR; Kodavanti, UP; Mehendale, HM, 1990
)
0.28
" CD, known to potentiate hepatotoxic and lethal effects of halomethanes in rats, failed to potentiate the toxic effects of any of these three halomethanes in gerbils."( Hepatotoxicity and lethality of halomethanes in Mongolian gerbils pretreated with chlordecone, phenobarbital or mirex.
Cai, Z; Mehendale, HM, 1991
)
0.49
", the estimation of parameters in the model used to convert animal doses into equally toxic human doses."( Fitting a model to categorical response data with application to species extrapolation of toxicity.
Hertzberg, RC, 1989
)
0.28
" These results indicate that photomirex was approximately five times more toxic than mirex in terms of liver histology."( Subchronic toxicity of photomirex in the female rat: results of 28- and 90-day feeding studies.
Becking, GC; Chu, I; Secours, V; Sundaram, A; Villeneuve, DC, 1980
)
0.83
" The LD50 were determined by the method of moving averages."( Acute hepatotoxicity and lethality of CCl4 in chlordecone-pretreated rats.
Klingensmith, JS; Lockard, V; Mehendale, HM, 1983
)
0.27
" In all cases, the cumulative LD50 for photomirex was estimated as 225-250 mg/kg."( Assessment of photomirex toxicity in the mouse.
Fujimori, K; Ho, IK; Mehendale, HM, 1980
)
0.85

Pharmacokinetics

ExcerptReferenceRelevance
" time was used to provide estimates of the values of the first-order rate constants required by the proposed pharmacokinetic models."( Mirex kinetics in the rhesus monkey. II. Pharmacokinetic model.
Pittman, KA; Treble, DH; Wiener, M,
)
1.57

Dosage Studied

The significant depletion of hepatic cytosolic GR in all experimental groups dosed with mirex failed to impair both uninduced and dexamethasone-induced TAT levels. Approximately 38--42% of the orally dosed photomirex was excreted in the feces in the first 3 days and 51--55% was eliminated in 28 days.

ExcerptRelevanceReference
"14C-Mirex was given iv and po to female rhesus monkeys (Macaca mulatta) and radioactivity was measured in plasma, urine, and feces at intervals after dosing and in tissues when animals were killed."( Mirex kinetics in the rhesus monkey. II. Pharmacokinetic model.
Pittman, KA; Treble, DH; Wiener, M,
)
2.13
" Approximately 38--42% of the orally dosed photomirex was excreted in the feces in the first 3 days and 51--55% was eliminated in 28 days."( The absorption, distribution and excretion of photomirex in the rat.
Becking, GC; Benoit, F; Chu, I; Secours, V; Viau, A; Villeneuve, DC,
)
0.64
"05) associated with dietary mirex was detected in the analysis of eggshell weight for chickens; however, because a dose-response relationship of shell weight vs."( The effect of mirex on reproduction of Japanesequail and on characteristics of eggs from Japanese quail and chickens.
Cox, JH; Davison, KL; Graham, CK, 1975
)
0.91
" Although a temporal relationship between the GSH levels and the GRc maximum binding concentrations in vivo was observed, there was no quantitative relationship between these two parameters based on our phorone dose-response and the carcinogen pretreatment data."( Phorone (diisopropylidene acetone), a glutathione depletor, decreases rat glucocorticoid receptor binding in vivo.
Chiesa, A; Sunahara, GI, 1992
)
0.28
" The significant depletion of hepatic cytosolic GR in all experimental groups dosed with mirex failed to impair both uninduced and dexamethasone-induced TAT levels in these groups."( Regulation of glucocorticoid receptors during adaptive liver growth.
Thottassery, JV; Yarbrough, JD, 1991
)
0.5
" Female Sprague-Dawley rats were orally dosed with mirex (12."( Mirex exposure inhibits the uptake of estradiol-17 beta(beta-D-glucuronide), taurocholate, and L-alanine into isolated rat hepatocytes.
Teo, S; Vore, M, 1990
)
1.97
" Male Sprague-Dawley rats were orally dosed with corn oil, mirex (50 mg/kg), or chlordecone (18."( Mirex inhibits bile acid secretory function in vivo and in the isolated perfused rat liver.
Teo, S; Vore, M, 1991
)
1.97
" Following the pretreatment at various time intervals ranging from 10 to 96 hr, groups of animals received a challenging dosage of CHCl3 (0."( Modifications in rat hepatobiliary function following treatment with acetone, 2-butanone, 2-hexanone, mirex, or chlordecone and subsequently exposed to chloroform.
Ayotte, P; Hewitt, LA; Plaa, GL, 1986
)
0.49
" There was a significant decrease in the total concentration of cytosolic binding sites for [3H]dexamethasone 12 and 48 hr after mirex dosing in intact rats, 12 and 48 hr after mirex dosing in adrenalectomized rats, and 12 and 24 hr after mirex dosing in adrenalectomized corticosterone-supplemented rats."( Alterations in the hepatic glucocorticoid response to mirex treatment.
Brown, LD; Wilson, DE; Yarbrough, JD, 1988
)
0.73
" The uptake of [14C]mirex during the initial 6 hr after dosing in all other tissues studied (liver, kidney, testes, and omental fat) was essentially the same for the three treatment groups."( Mirex uptake and tissue disposition in intact and adrenalectomized rats.
Brown, LD; Yarbrough, JD, 1988
)
2.04
" In partially hepatectomized rats dosed with mirex 24 h post-surgery, there was a dose-dependent increase in relative liver weight which peaked at 5 days."( A comparison of mirex-induced liver growth to liver regeneration.
Karl, PI; Yarbrough, JD, 1984
)
0.87
"The effect of two dietary treatments upon fecal excretion of Mirex was studied in rhesus monkeys dosed with 14C-Mirex."( Enhanced fecal excretion of mirex in rhesus monkeys by 5% mineral oil in the diet.
Greim, H; Rozman, K; Rozman, T; Williams, J, 1981
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
persistent organic pollutantAny environmental contaminant that is resistant to environmental degradation through photolytic, biological or chemical processes. Such substances can have significant impact on health and the environment, as they persist in the environment, bioaccumulate in animal tissue and so biomagnify in food chains.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organochlorine insecticideAny organochlorine pesticide that has been used as an insecticide.
chlorocarbonCompounds consisting wholly of chlorine and carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency2.45410.000221.22318,912.5098AID743053
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.30600.000229.305416,493.5996AID743079
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency1.72290.000627.21521,122.0200AID743202
Cellular tumor antigen p53Homo sapiens (human)Potency0.76960.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID289345Octanol-water partition coefficient, log KOW of the compound2007Science (New York, N.Y.), Jul-13, Volume: 317, Issue:5835
Food web-specific biomagnification of persistent organic pollutants.
AID289348Biomagnification factors in human2007Science (New York, N.Y.), Jul-13, Volume: 317, Issue:5835
Food web-specific biomagnification of persistent organic pollutants.
AID289346Octanol-air partition coefficient, log KOA of the compound2007Science (New York, N.Y.), Jul-13, Volume: 317, Issue:5835
Food web-specific biomagnification of persistent organic pollutants.
AID289347Biomagnification factors in Diporeia2007Science (New York, N.Y.), Jul-13, Volume: 317, Issue:5835
Food web-specific biomagnification of persistent organic pollutants.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (314)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990230 (73.25)18.7374
1990's29 (9.24)18.2507
2000's21 (6.69)29.6817
2010's26 (8.28)24.3611
2020's8 (2.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.96 (24.57)
Research Supply Index5.91 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index116.09 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (66.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.27%)5.53%
Reviews11 (3.01%)6.00%
Case Studies1 (0.27%)4.05%
Observational0 (0.00%)0.25%
Other352 (96.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]